The effects of endogenous and exogenous hyperglucagonemia on the specific binding of glucagon to hepatocyte receptors was studied, as was the response of cAMP to glucagon. In streptozotocin diabetic rats, blood glucose and plasma glucagon increased and plasma insulin decreased as compared with controls. Insulin treatment in diabetic rats restored blood glucose and plasma glucagon toward normal and elevated plasma insulin. Specific binding of 125 I-glucagon to isolated hepatocytes (10 6 cells) decreased in diabetic rats (8.17±0.38%) compared to controls (14.05±0.87%) and was restored by insulin treatment (12.25±0.93%). Specific binding of 125 I-insulin in controls was 7.30±10.16%; it increased in diabetic rats to 12.50±0.86%, and decreased in diabetic rats after insulin treatment (9.08±0.87%). Scatchard analysis and the competition plots of the data indicate that decreased glucagon binding and increased insulin binding in diabetes were due to change in the number of receptors rather than a change in their affinity. Hepatocyte cAMP response to glucagon (0.25-5.0 ng/ml) was almost abolished in diabetic rats and was restored with insulin treatment.
A B S T R A C T The effects of endogenous and exogenous hyperglucagonemia on the specific binding ofglucagon to hepatocyte receptors was studied, as was the response of cAMP to glucagon. In streptozotocin diabetic rats, blood glucose and plasma glucagon increased and plasma insulin decreased as compared with controls. Insulin treatment in diabetic rats restored blood glucose and plasma glucagon toward normal and elevated plasma insulin. Specific binding of 1251-glucagon to isolated hepatocytes (106 cells) decreased in diabetic rats (8.17±0 .38%) compared to controls (14.05±0.87%) and was restored by insulin treatment (12.25±0.93%). Specific binding of 1251-insulin in controls was 7.30±10.16%; it increased in diabetic rats to 12.50±0.86%, and decreased in diabetic rats after insulin treatment (9.08±0.87%). Scatchard analysis and the competition plots of the data indicate that decreased glucagon binding and increased 'insulin binding in diabetes were due to change in the number of receptors rather than a change in their affinity. Hepatocyte cAMP response to glucagon (0. .0 ng/ml) was almost abolished in diabetic rats and was restored with insulin treatment.
Specific glucagon binding by hepatocytes from chronically hyperglucagonemic (glucagon injected) rats was decreased (P < 0.005) to 8.76±0.61% compared with controls (13.20±0.74%) and acutely hyperglucagonemic animals (13.53±1.33%). The decreased binding was associated with a 70% decrease in hepatocyte cAMP response to glucagon compared with a normal response in acutely hyperglucagonemic rats.
INTRODUCTION
The diabetic state in both animals and man is characterized by a relative or absolute deficiency of insulin (1, 2) . In the presence of intestinal or pancreatic sources of glucagon, diabetes is accompanied by an absolute or relative increment in plasma immunoreactive glucagon (IRG)' (3) . IRG levels progressively rise as the diabetic syndrome becomes more severe, e.g., in diabetic ketoacidosis (4, 5) , the levels of IRG may increase as much as 100-fold over normal fasting plasma levels of40-100 pglml. The correction of the metabolic abnormalities of the diabetic state by insulin treatment is accompanied by a reduction in plasma IRG toward normal (6, 7) . These changes have been documented in both experimental animals and human diabetic subjects.
A highly significant inverse correlation has been demonstrated between the circulating plasma levels of insulin (IRI) and insulin binding to specific receptors in the experimental diabetic animal (8, 9) , as well as in the hyperinsulinemic diabetic patient (10) (11) (12) manner, the effect of' exogenous hyperglucagonemia upon glucagon binding in normal rats was also studied.
The observations support an inverse correlation between elevated plasma levels of IRG and specific glucagon binding under conditions of chronic, but not acute, hyperglucagonemia. Further, the alterations in glucagon binding are shown to correlate with the biological effectiveness of the glucagon molecule as measured by the formation of cAMP.
METHODS
Male Sprague-Dawley rats (Flow Laboratories, Dublin, Va.) weighing 120-150 g were used for all studies. Two types of studies were conducted. In the first, rats were made diabetic by injecting 85 mg/kg streptozotocin (Calbiochem, San Diego, Calif.) through the femoral vein after an overnight fast. They were allowed free access to f'ood and water but were supplemented with 5% glucose in water for the first 2 days after injection. The animals were sacrificed 5-10 days later when their blood glucose levels rose to >400 mg/100 ml. After 5 days, some diabetic animals were treated for an additional 5 days with subcutaneously administered isophane insulin, 5 U/ day (Eli Lilly and Co., Indianapolis, Ind.). All animals were studied in the fed state and sacrificed at approximately the same time of day. The rats were anesthetized with 100 mg/kg i.p. sodium amobarbital (Amytal, Eli Lilly and Co.), and blood was collected f'rom the abdominal aorta into tubes containing 1,000 U Trasylol (FBA Pharmaceuticals, Inc., New York) and 10.5 mg EDTA and hepatocytes were prepared.
In the second study, the effect of acute infusion or chronic injection of porcine pancreatic glucagon (Eli Lilly and Co.) was assessed on glucagon binding in fed normal rats.
Infusion. The rats were anesthetized by amytal, and glucagon (2 mg/2 ml) was infused through the femoral vein over a 2-h period, using a Harvard pump (Harvard Apparatus Co. Inc., Millis, Mass.). Control animals were infused with 2 ml saline over a 2-h period.
Injection. The rats were injected intramuscularly with 100 ,ug glucagon twice daily for 7 days. No injection was given on the day of sacrifice. The rats were anesthetized and the hepatocytes were prepared.
Blood glucose was measured by the glucose oxidase method using a protein-free filtrate. Plasma immunoreactive insulin (IRI) was measured according to Morgan and Lazarow (13) , and plasma IRG was assayed according to Unger et al. (14) using antibody 30K. Hepatocytes were prepared by the collagenase (CLS IV, Worthington Biochemical Corp., Freehold, N. J.) digestion of liver according to Zahlten and Stratman (15) with the addition of 5 mg/100 ml soybean trypsin inhibitor (Sigma Chemical Co., St. Louis, Mo.) (16) . The viability of the cells was checked by the trypan blue exclusion technique and found to be >95%.
1251-Glucagon and 1251-insulin were prepared according to Hunter and Greenwood (17) , as modified by Giorgio et al. (18) , sp act = 0.20-0.4 and 0.1-0.2 mCi/nmol, respectively. Carrierfree 1251-iodine was purchased from New England Nuclear, Boston, Mass. Pancreatic porcine insulin and pancreatic porcine glucagon were gifts from Eli Lilly and Co.
The iodinated insulin preparations were demonstrated to have biological activity equivalent to unlabeled hormone as measured by [14C]glucose conversion to "4CO2 in isolated adipose tissue (19, 20) . The activity of 1251-glucagon preparations was demonstrated in isolated hepatocytes by measuring cAMP formation (20, 21) .
To measure insulin binding, 106 cells were incubated for 30 min at 20°C in a final volume of 0.2 ml of a 0. ratio of counts in the supernate to the total counts determined the percent of added honnone which was degraded. To measure insulin degradation, 10% trichloroacetic acid (TCA) was used instead of the charcoal-Dextran mixture. The biological response of cells to glucagon was studied by measuring the cAMP formation in the presence of 0-10 ng porcine glucagon/ 3.75 x 106 hepatocytes in a final volume of 2.0 ml by the method described previously (21) .
RESULTS
Studies involving endogenous hyperglucagonemia. Blood glucose, plasma IRI, and plasma IRG values in normal controls, streptozotocin-treated diabetic rats, and insulin-treated diabetic rats are shown in Table I .
Injecting 85 Ag/kg streptozotocin raised the level of blood sugar three-fold in 5 days. When these animals were treated with 5 U isophane insulin/day for 5 days, the blood sugar returned to normal. Plasma IRI significantly decreased in diabetic rats, and plasma IRG increased to twice the normal level. On insulin treatment, plasma IRI increased significantly and plasma IRG decreased towards control values.
Hepatocytes obtained from diabetic rats, insulin-treated diabetics, and normal controls showed linearity for both glucagon and insulin binding as related to the number of cells (25 x 104-2.5 x 106). Insulin binding Fig. 2A shows the Scatchard plot of glucagon binding by controls, diabetic, and insulin-treated diabetic rat hepatocytes. Both the total glucagon bound, as well as the initial bound to free (B/F) ratio, were lower in diabetic rats as compared with controls. On insulin treatment, the initial B/F ratio increased toward the values obtained with control animals, whereas total glucagon bound increased beyond the normal levels. Since the intercept on the abscissa is taken as a measure of the number of receptors, the decreased glucagon binding in diabetic rats appears to be due to a decrease in the number of receptors. The Scatchard plot for insulintreated diabetic rats is not parallel to that of normal or untreated diabetics. It is steeper during the initial part of the curve, which suggests that there may be a change in the affinity of receptors. When the same data are plotted as percent of maximum specific binding against total glucagon present in the incubation medium (Fig.  2B) , there is no significant difference between the three curves. This indicates that despite the suggestive affinity change in Fig. 2A , there is no significant difference in the affinity of receptors among the three groups.
Similar analyses of insulin binding to the hepatocytes from the three groups are shown in Fig. 3A and B. Fig.  3A shows that the increased insulin binding by hepatocytes from diabetic rats was due to an increase in the number of receptors and that on insulin treatment, insulin binding decreased due to a decrease in the number of receptors. As seen in Fig. 3B , there was no significant difference in the affinity of hepatocytes for insulin in controls, diabetic, or insulin-treated diabetic rats.
To rule out the possibility that decreased glucagon binding in diabetic rats could have been due to factors such as increased glucagon degradation, the degradation of both insulin and glucagon by hepatocytes was examined. There was no significant difference in the amount of insulin degraded by hepatocytes (Table II) obtained from controls, diabetic, or insulin-treated diabetic rats. Degradation of glucagon by hepatocytes was also not altered in diabetes. However, there was significantly greater degradation (P < 0.05) of glucagon by hepatocytes from insulin-treated diabetic rats when compared with hepatocytes from either normal or untreated diabetic rats. The significance of this observation is not clear.
Since plasma IRG levels were higher in diabetic rats, it seemed pertinent to determine whether binding changes could have been due to differences in the amount of glucagon endogenously bound to the cells. The liver cells of controls and untreated diabetic rats were extracted for glucagon (24) were no significant differences between control and diabetic hepatocytes. (Table IV) .
Scatchard analysis of glucagon binding (Fig. 6A) shows that decreased binding in glucagon injected rats was due to decrease in the number of receptors. The competition curves (Fig. 6B) show no change in the apparent affinity ofglucagon binding in glucagon injected or infused rats. As seen in Fig. 7A (5) C G-lni (11) (6) 61nf. (5) GLUCAGON BINDING INSUUN BINDING ured by the production of cAMP (Fig. 8 Glucagon (ng/tube) FIGURE 6 (A) Scatchard analysis and (B) competition curves of glucagon binding to hepatocytes from control (C), glucagon-injected (G-Inj.), and glucagon-infused (G-Inf.) rats. Curves for control are the mean of 11 separate experiments. The curves for glucagon-injected rats are the mean of six separate experiments, whereas the curves for glucagon-infused rats are the mean of five separate experiments. For other details, refer to Fig. 2 . the fractionation procedures required to obtain membranes of high quality. One example of this is found in the observation that in all membranes from diabetic animals, the 5'-nucleotidase is reduced to 50% of controls. Further, in our hands, insulin treatment restored the nucleotidase concentration towards control levels. Details of these studies will be published separately. As a result of these problems in the use of membranes, our studies were conducted with isolated hepatocytes. In this study evidence is presented indicating that glucagon binding was significantly decreased in hepatocytes obtained from streptozotocin diabetic rats and that with insulin treatment, this binding returned to wards normal. Insulin binding, on the other hand, was increased in hepatocytes from untreated diabetics and decreased with insulin treatment. This latter observation is wholly consistent with the data of Davidson and Kaplan (8) obtained with liver plasma membranes from streptozotocin diabetic rats. However, these authors failed to observe any change in glucagon binding. This failure may be due to the fact that there is wide variation in hormone binding by membrane preparations both from individual animals and groups (26) . Davidson and Kaplan (8) examined only one membrane preparation from diabetic rats for glucagon binding.
In an effort to understand why glucagon binding was decreased and insulin binding was increased in experimental diabetes, it seemed reasonable to consider the following possibilities: affinity for the hormone; (b) a change in the affinity of the receptors with no corresponding change in their number; (c) a change in the number and affinity of the receptors; or (d) a change in the amount of degradation of either the hormone or the receptor. These possibilities were approached by subjecting the data to a Scatchard analysis and by plotting competition curves (percent maximum specific binding vs. total hormone concentration) to obtain an estimate of the apparent affinity of receptor for hormone. The Scatchard plots for glucagon binding in all animal groups were curvilinear ( Fig. 2A) , suggesting the existence of negative cooperativity as described by DeMeyts et al. (27, 28) 2B ) revealed no significant changes in affinity, but only an increase in receptor number ( Fig. 2A) . The effect of insulin treatment on insulin binding also was related to a change in receptor number, namely a decrease, but not a change in affinity (Fig. 3A, B) . Similar findings have been reported by Davidson and Kaplan (8) in liver plasma membranes of insulin-treated diabetic rats and by Kobayashi and Olefsky (29) in adipocytes of insulin-treated normal rats.
Since the plasma levels of IRG in diabetic rats were more than twice the levels in control rats, the possibility was raised that the hepatocyte receptors in diabetics, relative to receptors from animals with lower plasma IRG levels, might be partially saturated with glucagon.
Our studies of IRG levels extracted from hepatocytes of normal and diabetic animals revealed no differences, making this an unlikely explanation for the reduced glucagon binding in diabetics. With regard to the decreased number of insulin receptors after insulin treatment, the data from several laboratories (30) (31) (32) (33) indicate the ready dissociation of insulin from cells and membranes, thus eliminating the possibility of an endogenous saturation of receptors.
Another factor to be considered in the analysis of altered binding relates to degradation of the respective hormone. Ouir data provided evidence that no alteration in glucagon degradation occurred in untreated diabetic rat hepatocytes as compared to those of normal rats.
Insulin degradation was unaltered in hepatocytes from either untreated or insulin-treated diabetic rats. Davidson and Kaplan (8) made similar observations on insulin degradation by plasma membranes of control and untreated diabetic rats. Our data did show increased glucagon degradation in cells from insulin-treated diabetic rats. At the present time, we have no explanation for this phenomenon, though it deserves further exploration. The fact that there was no correlation between binding of glucagon and its degradation suggests that the two processes are independent of each other.
Having accepted that the number of glucagon receptors was decreased in the diabetic state and normalized with insulin treatment, one must raise the questions of "why" and "how" this occurs. The theory of receptor "down regulation" namely decreased hormone binding by specific receptors in response to elevation of hormone levels, has been well documented for insulin (8, 20, 34, 35) . Our observations with regard to glucagon binding in diabetics were consistent with a similar regulatory process in that high concentrations of plasma IRG were associated with decreased numbers of' receptors, and insulin treatment of these diabetic rats was accompanied by decreased plasma IRG (P < 0.05) and increased numbers of glucagon receptors.
To test this hypothesis of glucagon receptor regulation by hormone levels in a more direct manner, we studied the effect of glucagon injection and infusion on receptor binding. It was clear that short-term elevation of plasma glucagon (2 h of hyperglucagonemia as seen in our glucagon-infused rats) did not decrease hepatocyte glucagon binding. On the other hand. prolonged hyperglucagonemia (normnal rats injected with glucagon for 1 wk) decreased the glucagon receptor number.
A similar time requirement for the effects of hyperinsulinism on specific receptors has been shown by Kahn et al. (36) and Gavin et al. (34) .
Our studies with exogenous hyperglucagonemia strongly support, but do not absolutely prove, the hypothesis that the decrease in the receptor number is due to the regulation of glucagon receptors by the elevated plasma-glucagon level. Other factors in addition to hormone concentration and duration of exposure of the receptor to increased levels of hormone may influence or regulate binding of hormone. At least three possible factors come to mind: (a) The enhanced effect of endogenous (diabetes) vs. exogenous hyperglucagonemia (injected) in decreasing receptor number may be due to direct delivery of the forrmer to hepatic cell receptors; (b) Insulin, other than in its effect on decreasing glucagon levels, may influence receptors in as yet undefined "anabolic" fashion; and (c) Differential effects of various glucagon moieties in decreasing receptor number may depend upon the molecular species which is increased. In diabetic Glucagon Receptors in Diabetic Rats plasma and with exogenous glucagon, the increased molecular species is the 3,500-mol wt pancreatic type glucagon. This molecule is clearly biologically active. In chronic renal disease, the major component in plasma is a 9,000-mol wt molecule, probably proglucagon (37, 38) . This component may not only be biologically inactive, but also may not be able to bind to the glucagon receptor. Such an effect may explain the failure to observe a decrease in glucagon receptors in the hyperglucagonemia of experimental kidney disease (39) . Obviously much work remains to be done to clarify this area of glucagon receptor regulation.
What are the effects of decreased numbers of glucagon receptors in the diabetic and in glucagon injected rats? We observed that cAMP response to glucagon was markedly decreased in glucagon-injected and in diabetic rat hepatocytes. Treatment of the diabetic animals with insulin restored this response to normal. In general, these biological effects correlated with the alterations in glucagon binding. In the diabetic rat, glucagon binding was reduced by 40% and the cAMP response to glucagon was essentially abolished. Similarly, in the glucagon-injected rat, binding was decreased by 30% and glucagon-induced cAMP formation was decreased by >70%.
How can one account for the quantitative discrepancy in glucagon binding vs. cAMP formation? A number of hypotheses may be suggested: (a) Specific glucagon receptors may be heterogeneous; 20% may be true receptors capable of activating cAMP formation, whereas 80% may more properly be called acceptors in that they bind hormone but cannot activate the adenylate cyclase, and that the decrease in the number of receptors may be more pronounced in the small active receptor population rather than in the inactive acceptor population. (b) Problems in the transfer of membrane receptor signals to the enzyme may exist (40) . (c) Intracellular alterations such as ATP deficiency, which may interfere with enzyme action, could occur. Such an alteration might readily be restored by insulin.
It is noteworthy that basal hepatic levels of cAMP have been reported to be elevated in diabetes (41) (42) (43) and in starvation (41, (44) (45) (46) . Fouchereau-Peron et al. (47) reported that glucagon binding and cAMP response to glucagon were reduced in starvation, a situation somewhat analagous to diabetes. Thus, the mechanisms by which starved and diabetic livers develop elevations of cAMP would appear to be glucagon independent.
In conclusion, endogenous hyperglucagonemia in uncontrolled diabetes, as well as prolonged exogenous hyperglucagonemia, are associated with a decrease in the number of glucagon receptors and impaired cAMP response to glucagon. If one were to reason teleologically, the decrease in glucagon receptors and the marked decrease in the biological effect of glucagon in diabetes could provide a mechanism for reducing the excessive gluconeogenesis and hyperglycemia associated with the diabetic state.
